Speakers

Expand/Collapse

Aaron Nolan
Consultant
Eli Lilly and Company

Day One

2:00 pm | Case Study on Supplier Spend Analytics for Clinical Trials

David Karakas
Director, Sourcing & Procurement
Bluebird Bio

Day Two

2:30 pm | Strategic Sourcing for Rare Diseases & Emerging Therapeutics

Rinaldo Dorman
Procurement Lead
Cerevel

Day One

11:55 am | Discussion: Vendor Oversight and Risk Management Approaches Across the Pharma Industry

Andrew Wolfe
CEO
Wolfe Procurement

Gerard Cardillo
Executive Director
Charles River Labs

Day Two

2:00 pm | Importance of Pre-Emptive Thinking in Procurement of NHP’s for Ultimate Product Approval

Umar Salahuddin
Director, Research, Development & Sourcing
Biogen

Day One

11:55 am | Discussion: Vendor Oversight and Risk Management Approaches Across the Pharma Industry

Penelope Przekop
CEO
PDC Pharma Strategy

Limor Glick
Director, Strategic Sourcing
Sunovion Pharmaceuticals

Day One

11:55 am | Discussion: Vendor Oversight and Risk Management Approaches Across the Pharma Industry

Anca Copaescu
Founder & CEO
Strategikon Pharma

Day One

2:30 pm | Case Study: Automating and Harmonizing RFP Processes for a Phase 3 Neurodegenerative Rare Disease Clinical Trial Using Clinical MaestroTM

Wanlu Liu
Global Lead Sourcing Manager
Takeda

Day Two

11:20 am | Speaker Interview Followed by Debate: Single vs Dual vs TriSourcing – How Takeda Realigned their Sourcing Strategy Post Shire Acquisition

Kris Ward
Director, Procurement
Orchard Therapeutics

Day One

10:25 am | Vendor Management vs. Category Management – Orchard Therapeutics’ Journey to Support an Increasingly Complex and Global Business

Joe Carvalho
Director, Global Category Manager Scientific Services
Novartis

Day One

5:45 pm | Chair’s Closing Remarks

9:40 am | The Current R&D Procurement Landscape and the Comeback of Supplier Relationship Management (SRM) in the R&D Program

9:30 am | Chair’s Opening Address

Day Two

3:00 pm | Chair’s Closing Remarks

9:30 am | Chair’s Opening Remarks

Thierry Fausten
Researcher, Canfield University; Former Head of Procurement (NW Africa)
Roche

Day Two

10:10 am | Bridging the Gap Between Pre-Clinical and Clinical: How Early Stakeholder Engagement Aids SRM in Achieving End-to-End Business Development

Karan Paruvangada
Strategic Sourcing Leader
Bill and Melinda Gates Medical Research Institution

Day One

5:15 pm | Innovative Sourcing Approaches from the Bill and Melinda Gates Medical Research Institution

Rose Prisco
Associate Director Clinical Procurement
Pacira Pharmaceuticals

Day One

4:45 pm | Contracting – Who Drives the Content

Olivier Steinmetz
Head of R&D Third Party Quality
GSK

Day One

12:30 pm | A fit-for-purpose R&D third party technical assessment – GSK Vaccines’ simplification of R&D partner’s compliance evaluation.

Martisse Best
Senior Director, Strategic Sourcing
IQVIA

Day Two

9:40 am | Virtual Trial Triumphs

Victoria Woodward
Procurement Professional
Indivior

Day Two

1:30 pm | Mastermind: Forging the Next Generation of Procurement Professionals in R&D – What is the Ideal Procurement Resume?

Tom Thattacherry
Head of Supplier Diversity
Roche/ Genentech

Tom heads the Supplier Diversity for Roche/Genentech. He is actively engaged in creating strategies, building partnerships cross divisionally with stakeholders, sourcing, business partners and suppliers to drive small/diverse business inclusion opportunities in the supplier base. He also works with the U.S. Government entities such as U.S Small Business Administration and the Department of Veterans Affairs on small business subcontracting plans and regulations.   Tom is a past President of the Board of Directors for Diversity Alliance for Science, Inc. a national non-profit organization focused on developing diverse owned businesses in the Life Sciences industry. He is also actively engaged with a number of national and local diverse supplier advocacy groups and is a certified Integral Coach. Tom has been in the pharma industry for over 18 years.

Day Two

12:00 pm | Benefits of Supplier Diversity from Morals to Macroeconomics